Popular terms

Immune Disease topics
Immune Disease
Autoimmune
Autoimmune Disease
Immune Diseases
Autoimmune Diseases
Immune Disorder
Transplant
Autoimmune Disorders
Type 1 Diabetes
Autoimmune Disorder
Proliferative Disorder
Signs And Symptoms
Proliferative
Antagonist
Recurrence

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immune Disease patents

      

This page is updated frequently with new Immune Disease-related patent applications.




Date/App# patent app List of recent Immune Disease-related patents
08/18/16
20160237168 
 Methods for treating and preventing multiple sclerosis patent thumbnailMethods for treating and preventing multiple sclerosis
We have discovered that lrg-47 (also called p47 gtpase), plays a central role in the pathogenesis of multiple sclerosis, and that inhibition of lrg-47 activity by anti-lrg-47 antibodies or of lrg-47 expression by sirna dramatically reduce the pathology and symptoms of multiple sclerosis. Certain embodiments of the invention are directed to the therapeutic use of anti-lrg-47 antibodies (mouse or rabbit or other antibodies that are humanized or human antibodies to lrg-47, preferably antibodies made against human lrg-47) or sirna or antisense nucleotides that specifically hybridize with the gene or mrna or cdna encoding human lrg-47 to treat or prevent multiple sclerosis and other autoimmune diseases that are t-cell-mediated.
The Trustees Of Columbia University In The City Of New York


08/18/16
20160237154 
 Antibody therapeutics that bind ctla4 patent thumbnailAntibody therapeutics that bind ctla4
There is disclosed compositions and methods relating to or derived from anti-ctla4 antibodies. More specifically, there is disclosed fully human antibodies that bind ctla4, ctla4-antibody binding fragments and derivatives of such antibodies, and ctla4-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.


08/18/16
20160237152 
 Tspan 33 is a candidate for antibody targeted therapy for the treatment of b cell hodgkin lymphomas patent thumbnailTspan 33 is a candidate for antibody targeted therapy for the treatment of b cell hodgkin lymphomas
A method of treating a disease associated with activated b lymphocytes expressing tetraspanin 33 (tspan33/baam). The disease can be, for example, lymphoma or an immune disease.
Universidad Autonoma De Nuevo León


08/18/16
20160237075 
 Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease patent thumbnailSubstituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
And pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by bruton's tyrosine kinase (btk).. .

08/18/16
20160235872 
 Compositions and methods to image and quantify inflammation patent thumbnailCompositions and methods to image and quantify inflammation
Compositions and methods for assessing inflammation in a subject. The preset disclosure provides compositions for labeling leukocytes with a 19f-containing perfluoropolyether molecule ex vivo.
Celsense, Inc.


08/18/16
20160235683 
 Amorphous magnesium-substituted calcium phosphate compositions and their uses patent thumbnailAmorphous magnesium-substituted calcium phosphate compositions and their uses
Amorphous magnesium-substituted calcium, phosphate compositions and their medical uses are described, in particular for use in delivering cargo materials, such as cargo molecules or cargo nanoparticles contained in pores of the amorphous magnesium-substituted calcium phosphate to cells of the immune system, for example as therapeutic approaches for the treatment of inflammatory bowel diseases, and in particular crohn's disease, autoimmune diseases, allergy and for therapeutic vaccination.. .
Medical Research Council


08/11/16
20160229900 
 Engineered cxcl12 alpha locked dimer polypeptide patent thumbnailEngineered cxcl12 alpha locked dimer polypeptide
The present invention provides a novel cxcl12-α2 locked dimer polypeptide, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and hiv/aids.. .
The Rockefeller University


08/11/16
20160229892 
 Cyclic peptide conjugates and methods of use patent thumbnailCyclic peptide conjugates and methods of use
The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).. .
Modulation Therapeutics


08/11/16
20160229868 
 Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity patent thumbnailNovel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
A novel fused pyrimidine derivative has an inhibitory activity for tyrosine kinases. A pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases contains the fused pyrimidine derivative as an active ingredient..
Hanmi Science Co., Ltd


08/11/16
20160229860 
 Bicyclic alkyne derivatives and uses thereof patent thumbnailBicyclic alkyne derivatives and uses thereof
The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the map kinase interacting kinases mnk2a, mnk2b, mnk1a, and mnk1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prevention and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, autoimmune diseases, metabolic diseases, and neurodegenerative diseases (e.g.
Agency For Science, Technology And Research


08/11/16
20160229843 

Aza-heteroaryl compounds as pi3k-gamma inhibitors


And pharmaceutically acceptable salts thereof, wherein x, y, z, a, w, r4, r5, and r6 are defined herein, that inhibit the activity of phosphoinositide 3-kinases-gamma (pi3kγ) and are useful in the treatment of diseases related to the activity of pi3kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.. .

08/11/16
20160228561 

Protein-cell conjugate, preparation method and use thereof


The present invention pertains to immunology, biomedicine field, specifically relates to a protein-cell conjugate, which is characterized in that the protein and the cell are coupled via a bifunctional cross-linking agent. The present invention further relates to a preparation method and uses of the protein-cell conjugate.
Cansbio (beijing) Biotechnology Co., Ltd.


08/11/16
20160228442 

Nitrogen-containing bicyclic aromatic heterocyclic compound


On the basis of a cathepsin s inhibitory effect, an excellent agent for treating or preventing autoimmune disease, allergic disease, graft rejection of an organ, bone marrow or tissue, systemic lupus erythematosus, or the like is provided. It was found that a nitrogen-containing bicyclic heterocyclic compound has an excellent cathepsin s inhibitory effect, thereby completing the invention.
Astellas Pharma Inc.


08/11/16
20160228434 

Treatment of diseases caused by abnormal lymphocyte function with an hdac6 inhibitor


An hdac6 inhibitor (a compound of formula i) is shown to reduce the pathogenesis associated with the b cell mediated autoimmune disease, systemic lupus erythematosus (sle) administration of a compound of formula i attenuated many of the symptoms characteristic of sle including splenomegaly, abnormal b cell differentiation, an increase in the number double-negative thymic t cells, an increase in the level of auto-antibodies such as anti-dsdna, immune complex-mediated glomerulonephritis and an increase in inflammatory cytokine production. Treatment with a compound of formula i also increased the number of the subject's splenic treg cells while removing circulating auto-antibodies inhibition of hdac6 altered bone marrow b cell differentiation by increasing the percentage of cells in the early-stage developmental fractions of both pro- and pre-b cells.
Virginia Tech Intellectual Properties, Inc.


08/04/16
20160222113 

Antibodies against pd-1 and uses thereof


The present invention provides antibodies and antigen-binding fragments that specifically bind pd-1 (programmed death 1), thereby modulating immune responses in general, and those mediated by tcr and cd28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer and other immune system disorders..
Medimmune Limited


07/28/16
20160215042 

Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins


Described herein are novel compositions comprising mt1 and/or mt2 modulators (i.e., inhibitors or activators), and methods using these agents for targeting different t-cell populations, for example, type 1 regulatory (tr1) cd4+ cells and exhausted cd8+ t-cells cells. Aspects of the invention relate to inhibitors of mt1 and/or mt2 to increase the differentiation of cd4+ cell trl1 cd4+ cells and increase in the activity of tr1 cells, e.g., to increase il-10 production.
The Brigham And Women's Hospital, Inc.


07/28/16
20160214994 

Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof


Disclosed are a fused pyrimidine compound, an intermediate, a preparation method therefor, and a composition and an application thereof. The present invention provides a fused pyrimidine compound shown in formula i, pharmaceutically acceptable salt, hydrate, solvate, and an optical isomer or prodrug of the compound.
Shanghai Yingli Pharmaceutical Co., Ltd


07/28/16
20160214986 

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders


Wherein r1a, r1b, r2, r4, r5, r6, r7, r8, w, x, y, z, cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (npp2 or enpp2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention..

07/28/16
20160214963 

Inhibitors of bruton's tyrosine kinase


Wherein r0, r1, r2, r3, r4, r5, and l are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds..

07/28/16
20160214951 

Ebi2 modulators


Provided herein are small molecule epstein-barr virus-induced g-protein coupled receptor 2 (ebi2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. Ebi2 is a therapeutic target for the treatment of a variety of diseases or conditions.
Sanford-burnham Medical Research Institute


07/28/16
20160214948 

Prodrugs of monomethyl fumarate (mmf)


The present invention relates to novel compounds for use as a medicament. In particular, the present invention relates to a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, inflammatory diseases, for example multiple sclerosis and psoriasis..
Ratiopharm Gmbh


07/28/16
20160213676 

Substituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis


The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the retinoic acid-related orphan nuclear receptor γt (rorγt)/rorγ. The compounds of the present invention are useful for modulating rorγt)/rorγ activity and for treating diseases or conditions mediated by rorγt)/rorγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as multiple sclerosis (ms), rheumatoid arthritis (ra), inflammatory colitis, psoriasis, copd, pain, obesity, diabetes, dyslipidemia, osteoporosis, asthma, neurodegenerative diseases and cancer..
Arrien Pharmaceuticals Llc


07/28/16
20160213666 

Novel compound useful for the treatement of degenerative and inflammatory diseases


A pyrazolopyridine compound according to formula i, able to inhibit jak is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant jak activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6..

07/28/16
20160213651 

Pidotimod for use in the treatment of inflammation-associated diseases


The present invention relates to a novel use of the active ingredient pidotimod, or its stereoisomers and/or physiologically acceptable salts thereof, to treat inflammation-associated diseases characterized by an aberrant hyperactivation of the non canonical nfkb pathway, such as allergic diseases, autoimmune diseases or other inflammatory diseases based on mechanisms different from allergic or autoimmune.. .
Polichem S.a.


07/28/16
20160213627 

Substituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis


The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the retinoic acid-related orphan nuclear receptor γt (rorγt)/rorγ. The compounds of the present invention are useful for modulating rorγt)/rorγ activity and for treating diseases or conditions mediated by rorγt)/rorγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as multiple sclerosis (ms), rheumatoid arthritis (ra), inflammatory colitis, psoriasis, copd, pain, obesity, diabetes, dyslipidemia, osteoporosis, asthma, neurodegenerative diseases and cancer..
Arrien Pharmaceuticals Llc


07/21/16
20160208217 

Method for enhancing therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases


A method for enhancing the therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases is provided. The method comprises pre-treating the stem cells with ligustilide to increase the expression of differentiation-promoting genes in the stem cells, increase the expression of homing-promoting genes in the stem cells, and/or decrease the expression of inflammatory genes in the stem cells, wherein the treatment is conducted in a culture medium of the stem cell..
Gwo Xi Stem Cell Applied Technology Co., Ltd.


07/21/16
20160208013 

Methods and compositions for reducing cardiac damage and other conditions


Endoglin has been identified to play a functional role as a regulator of tgfβ1 signaling, particular in tgfβ1-mediated calcineurin expression. The present invention features methods of reducing cardiac damage, particularly in a subject undergoing chemotherapy or radiation therapy by administering a composition that inhibits endoglin activity.
Tufts Medical Center, Inc.


07/21/16
20160208010 

Anti-human cd52 immunoglobulins


The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human cd52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain.
Genzyme Corporation


07/21/16
20160206756 

Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein


The present application describes a coding nucleic acid sequence, particularly a messenger rna (mrna), comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g.
Curevac Ag


07/21/16
20160206660 

Composition of stem cells having highly expressed fas ligand


This disclosure relates in general to a stem cell treatment. This disclosure further relates to a stem cell treatment using a composition comprising stem cells having highly expressed fas-l.
University Of Southern California


07/21/16
20160206611 

Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.




Immune Disease topics: Immune Disease, Autoimmune, Autoimmune Disease, Immune Diseases, Autoimmune Diseases, Immune Disorder, Transplant, Autoimmune Disorders, Type 1 Diabetes, Autoimmune Disorder, Proliferative Disorder, Signs And Symptoms, Proliferative, Antagonist, Recurrence

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.3345

5397

2 - 1 - 103